In Healthcare sector, shares of Protalix BioTherapeutics, Inc. (PLX) were valued at $0.77 and moved -3.76% as of a recent closing trade. A total volume of 0.4 million shares were traded versus to average volume of 1.43 million shares. Protalix BioTherapeutics, Inc. (PLX) shares have been seen trading -49.49% off its 52 week- peak value and changed 194.27% from its 52 week-bottom price value. The “percentage off the 52-week high or low” refers to when a stock current price is relative to where it has traded over the last 52 weeks. This gives investors an idea of how much the security has moved in the last year and whether it is trading near the top, middle or bottom of the range.
In terms of Protalix BioTherapeutics, Inc. (PLX) stock price comparison to its moving averages, shares of company are -10.89% away from the 50-day moving average and -6.51% away from 20-day average. If we take a long term observation, shares have been trading at a distance of 1.32% from the 200-day moving average. Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also facilitate in determining where it may be possibly heading.
The pros and cons of heating your home with a fireplace
Choosing a heating type might be one of the most important decisions you make for your home. Not only could you end up saving money upfront and in the future, the right type of heater can make your family healthier and improve your quality of life.
It pays to do your research before choosing what type of heating to install in your home, so we’ve rounded up some of the main pros and cons to get you started. But first…
Slower growth in demand is keeping world food prices low, The Organisation for Economic Co-operation and Development (OECD) says.
The latest OECD 10-year agricultural outlook predicts global food commodity prices to remain low over the next decade compared to previous peaks.
The report said demand in a number of emerging economies is expected to slow down and biofuel policies are having a diminishing impact on markets.
Researchers use expensive machinery to develop ways to harness DNA as a synthetic raw material to store large amounts of digital information outside of living cells.
But what if they could coerce living cells, such as large populations of bacteria, to use their own genomes as a biological hard drive that can record information scientists could tap anytime? That approach not only could open entirely new possibilities of data storage, it could also be engineered into an effective memory device able to create a chronological record of cells’ molecular experiences during development or under exposure to stresses or pathogens.
How to get smart, collaborative and go circular
If collaboration is king, governments, industry associations, communities and regions need a new armoury of policies and programs to advance talent and accelerate value-creating collaborations between companies.
Think UK with its open source and tax-friendly Patent Box legislation, a real boon to start-ups and SMEs. Or Scandinavian cluster programs with their matchmaking activities to foster innovation between SMEs so they can diversify into new markets, and their deep understanding of their industries’ dynamics. An example of such cluster mapping is the report Engineering the Green Economy on Northern Denmark’s win and energy cluster.
Good morning! Here’s the technology news you need to know this Wednesday.
1. Uber’s business is still growing despite months of bad news, scandals and turmoil. The company said its gross bookings for rides were up 10% from the previous quarter.
2. Analysts say that the “supercycle” that’s supposed to power iPhone 8 sales could just be a “cycle.” A note published by Deutsche Bank says that expectations for iPhone 8 sales are too high.
Meat and Livestock Australia is calling for applicants to its new GrowLab initiative to help agtech entrepreneurs commercialise beneficial technology for red meat industries.
GrowLab aims to develop selected innovations in areas such as robotics, animal health, remote sensing, food technologies and decision support tools.
Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and the largest sequencing capacity in the world. Through this agreement, Novogene will purchase NextCollect™, Trovagene’s proprietary urine collection and nucleic acid preservation device for validation in the Chinese market.
Trovagene will sell Novogene the NextCollect urine collection and stabilization device, in addition to reagents and methods to extract cell-free DNA (cfDNA) from urine. Novogene plans to validate the urine DNA extraction methods at their facilities, including their lab in Tianjin, China, which is accredited by the College of American Pathologists (CAP).
FIT Biotech Oy (‘Company’) has received today a EUR 644,868 payment from its HIV collaborator, the European HIV Vaccine Alliance (EHVA). The payment was received as part of the contracted scheduled payments for manufacturing the Company’s investigational DNA-based HIV vaccine for a large multicenter Phase I/2 clinical trial planned to initiate later this year. EHVA is financed by the Horizon 2020 program of the European Commission.
FIT Biotech manufactures the investigational DNA-based HIV vaccine for EHVA in its own GMP production facility in Tampere, Finland, that is approved by the Finnish Medicines Agency (Fimea). This facility has the capacity to produce investigational drugs up to Phase 2 clinical trials, thus ensuring a rapid capability to introduce new DNA-based drug candidates to clinical trials.
Third positive data review by IDSMB follows completion of patient recruitment.
Paris and Boston, July 11th, 2017 – Neovacs (Euronext Growth: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it received a positive data review by the Independent Data and Safety Monitoring Board (IDSMB) for the ongoing Phase IIb Clinical Trial of IFNα Kinoid in lupus.
This is the third IDSMB data review of the ongoing Phase IIb clinical trial. The board reviewed the cumulative data, notably safety data from the study and informed the company that it has identified no safety concerns, and recommended the continuation of the study without any modifications. The trial is now fully enrolled with 178 patients randomized to receive either injection IFNα Kinoid vaccine or placebo.